Algert Global LLC Supernus Pharmaceuticals, Inc. Transaction History

Algert Global LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	BUY	$28.79 - $35.41 $124,142 - $152,687	4,312 Added 50.09%	12,920 $437,000
Q2 2022 Aug 15, 2022	BUY	$25.33 - $34.25 $46,353 - $62,677	1,830 Added 27.0%	8,608 $249,000
Q1 2022 May 16, 2022	BUY	$28.51 - $32.9 $193,240 - $222,996	6,778 New	6,778 $219,000
Q4 2021 Feb 14, 2022	SELL	$26.37 - $34.22 $209,773 - $272,220	-7,955 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$23.54 - $31.39 $187,260 - $249,707	7,955 New	7,955 $212,000
Q1 2020 May 13, 2020	SELL	$14.45 - $24.69 $275,850 - $471,332	-19,090 Closed	0 $0
Q4 2019 Feb 18, 2020	SELL	$19.93 - $29.13 $478,977 - $700,081	-24,033 Reduced 55.73%	19,090 $453,000
Q3 2019 Nov 14, 2019	BUY	$25.47 - $33.37 $532,654 - $697,866	20,913 Added 94.16%	43,123 $1.19 Million
Q2 2019 Aug 14, 2019	BUY	$29.96 - $38.87 $103,421 - $134,179	3,452 Added 18.4%	22,210 $735,000
Q1 2019 May 01, 2019	SELL	$32.77 - $41.99 $216,445 - $277,343	-6,605 Reduced 26.04%	18,758 $657,000
Q4 2018 Feb 01, 2019	BUY	$30.84 - $49.51 $533,593 - $856,622	17,302 Added 214.64%	25,363 $843,000
Q2 2018 Aug 02, 2018	SELL	$44.1 - $59.85 $4.55 Million - $6.17 Million	-103,122 Reduced 92.75%	8,061 $482,000
Q1 2018 May 03, 2018	BUY	$37.15 - $46.9 $1.65 Million - $2.08 Million	44,320 Added 66.28%	111,183 $5.09 Million
Q4 2017 Feb 01, 2018	BUY	$36.4 - $42.6 $152,224 - $178,153	4,182 Added 6.67%	66,863 $2.66 Million
Q3 2017 Nov 17, 2017	BUY	$36.75 - $49.65 $2.3 Million - $3.11 Million	62,681	62,681 $2.51 Million

283

60.8M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.02B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.